Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration

Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections. This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.

NCT Number	NCT07423429
Lead Sponsor	Nantes University Hospital
Conditions	Exudative Age-Related Macular Degeneration
Enrollment	100 participants
Start Date	2026-02-20
Primary Completion	2026-10-20 (estimated)
Study Completion	2026-10-20 (estimated)
Updated on ClinicalTrials.gov	2026-06-25